GNPX — Genprex, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1595248 ·
Last close
$1.67
Market Cap
$1.37M
52W High
$93.94
52W Low
$1.66
ADV30
171,592
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -4,483,984 | -4,447,219 | 17,136,916 | 15,154,203 | 2,341,864 |
| Mar 2026 | 0 | — | -4,494,184 | -4,461,895 | 20,306,266 | 18,049,255 | 3,375,996 |
| Dec 2025 | 0 | — | -3,518,632 | -3,790,211 | 10,159,011 | 7,830,855 | 2,197,135 |
| Sep 2025 | 0 | — | -3,345,913 | -3,799,240 | 3,562,513 | 1,103,315 | 2,794,706 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,562,704
Investing CF
$0
Financing CF
$29,370,064
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-318.78
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-179,937,510
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-15,827,684
Pretax Income TTM
$-16,498,565
Interest Exp TTM
$739,935
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -15,515,619 | -16,228,953 | 10,159,011 | 2,197,135 | 7,961,876 | -15,311,209 |
| Dec 2024 | 0 | -21,174,167 | -21,111,163 | 4,124,325 | 2,504,170 | 1,620,155 | -17,922,566 |
| Dec 2023 | 0 | -31,056,894 | -30,860,461 | 10,670,592 | 3,254,208 | 7,416,384 | -24,738,603 |
| Dec 2022 | 0 | -23,830,719 | -23,740,621 | 25,085,027 | 2,810,287 | 22,274,740 | -17,621,498 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$24,482,135
NetIncome TTM
$-16,498,565
OpCashFlow TTM
—
Assets (Latest)
$17,136,916
Forward EPS
$-2.18
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KAPA | Kairos Pharma, LTD. | $1.35M | $0.40 | — |
| CPMD | CANNAPHARMARX, INC. | $1.42M | $0.00 | — |
| HCWB | HCW Biologics Inc. | $1.43M | $0.78 | — |
| AGNPF | Grey Matters Health Inc. | $1.30M | $0.24 | — |
| ISCO | International Stem Cell CORP | $1.28M | $0.16 | — |
News headlines (Yahoo Finance, 1h cache)
Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium
2026-11-11 12:00 · Yahoo
Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-A
2026-11-05 12:00 · Yahoo
Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer
2026-11-04 12:00 · Yahoo
Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting
2026-10-28 11:00 · Yahoo
Genprex Highlights New Preclinical Data Identifying Role of TUSC2, the Gene Used in REQORSA®, in Maintaining Cellular Function During Brain Aging
2026-10-21 11:00 · Yahoo
Genprex to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
Andelyn Biosciences to Scale Manufacturing for Genprex's Diabetes Gene Therapy Program
2026-09-01 12:00 · Yahoo
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy
2026-08-18 11:00 · Yahoo
Genprex Shares Rise After Collaboration With Roche Diagnostics
2026-08-03 12:46 · Yahoo
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
2026-08-03 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.